Alpha Cognition Delays Third-Quarter Results After Reporting 71% Growth in ZUNVEYL Revenue
Key Facts
Alpha Cognition’s third-quarter 2026 results, and its description of the period as the strongest quarter since ZUNVEYL’s launch, could not be verified because the results statement released on November 11 was not available in open sources. The company had scheduled the announcement for the same day at 4:30 p.m. Eastern time, after the market close. It said management would hold a call to review the financial and operating results after the statement was released. The third-quarter figures and claim of record performance therefore remain unconfirmed here. The latest documented figures available show the product’s growth in the second quarter, when revenue reached about $6.0 million.
ZUNVEYL revenue rose about 71% in the second quarter compared with first-quarter revenue of $3.5 million, according to Alpha Cognition. The sequential growth points to expanding sales during the first half of the year, but does not by itself establish third-quarter performance. In the first quarter, the company said the product generated about $3.5 million in net revenue, up 40% from the fourth quarter of 2025. It also reported cumulative net revenue of $10.3 million over the first four full quarters since launch. Those figures provide a backdrop of growing commercial momentum ahead of the third-quarter results announcement.
On volume, 8,294 prescriptions for the treatment were filled in the second quarter, up from 6,054 in the first quarter, a sequential increase of about 37%. The company said monthly prescription demand continued to rise throughout the quarter, reaching 2,997 in June. The number of prescribing health professionals also expanded to 1,347 in the second quarter. Of those, 1,024 were repeat prescribers, while 1,095 long-term-care facilities prescribed the treatment during the period. The company’s data link sales growth to an expanding base of prescribers and facilities.
On insurance coverage, Alpha Cognition said it had Medicare Part D contracts with two large pharmacy benefit managers, covering about 45 million people. It estimated that the total contracted business base was about 16% in the second quarter. These arrangements provide a framework for reaching covered patients, while their actual commercial impact remains tied to prescription levels and sales. The company has described ZUNVEYL as an approved treatment for mild to moderate Alzheimer’s dementia in adults. The product is at the center of its commercial operations, which markets track through product revenue and prescription growth indicators.
On financing, cash and cash equivalents stood at $41.4 million on June 30, 2026. The company said its current resources support its goal of reaching operating profitability in 2027. In the first quarter, operating expenses were about $11.6 million, and the company reaffirmed full-year expense guidance of about $54 to $58 million. These figures put spending and liquidity alongside product revenue growth, but on their own do not provide a read on the financial position at the end of the third quarter. The company had scheduled its review of the financial and operating results after the market close on November 11.
On the clinical front, the company announced that patient enrollment had begun in the interventional Phase 4 RESOLVE study. Alpha Cognition expects the study to be completed in the second quarter of 2027. The timeline follows a period of commercial expansion reflected in second-quarter data, while the study’s progress marks a later milestone in the product program. In an earlier statement, the company said the first quarter of 2026 was ZUNVEYL’s fourth full quarter of commercial operations. The chief executive at the time described the treatment as the first new oral Alzheimer’s treatment to receive approval in more than 15 years.